Androgen deprivation therapy as backbone therapy in the management of prostate cancer

Androgen deprivation therapy (ADT) is well established as a backbone therapy for metastatic prostate cancer (mPCa), and both European and American guidelines emphasize the importance of maintaining ADT after progression to metastatic castration-resistant prostate cancer (CRPC). However, the use of A...

Descripción completa

Detalles Bibliográficos
Autores principales: Merseburger, Axel S, Alcaraz, Antonio, von Klot, Christoph A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140029/
https://www.ncbi.nlm.nih.gov/pubmed/27942220
http://dx.doi.org/10.2147/OTT.S117176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140029/
https://www.ncbi.nlm.nih.gov/pubmed/27942220
http://dx.doi.org/10.2147/OTT.S117176

Ejemplares similares